Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatln and paclitaxel chemotherapy from two prospective phase I and II studies

Head and Neck

Volumn 27, Issue 5, 2005, Pages 406-414

  Kramer, Noel M ^a   Horwitz, Eric M ^a   Cheng, Jonathan ^a   Ridge, John A ^a   Feigenberg, Steven J ^a   Cohen, Roger B ^a   Nicolaou, Nicos ^a   Sherman, Eric J ^a   Babb, James S ^a   Damsker, Jason A ^a   Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Head and neck cancer; Hyperfractionated; Reirradiation; Squamous cell carcinoma

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLACEBO;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; FATIGUE; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; HYPOALBUMINEMIA; INFECTION; IRRADIATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SALVAGE THERAPY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR RECURRENCE; VOMITING; XEROSTOMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; PROSPECTIVE STUDIES; RETREATMENT; SALVAGE THERAPY; STOMATITIS; VOMITING;

EID: 17844373781     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20163     Document Type: Article

References (32)

1. Hong WK, Bromer R. Chemotherapy in head and neck cancer. N Engl J Med 1983;308:75-79.
2. Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984;53:1819-1824.
3. Emami B, Bignardi M, Spector GJ, Devineni VR, Hederman MA. Reirradiation of recurrent head and neck cancers. Laryngoscope 1987;97:85-88.
4. Langlois D, Eschwege P, Kramar A, Richard JM. Reirradiation of head and neck cancers. Presentation of 35 cases treated at the Gustave Roussy Institute. Radiother Oncol 1985;3:27-33.
5. Pomp J, Levendag PC, van Putten WL. Reirradiation of recurrent tumors in the head and neck. Am J Clin Oncol 1988;11:543-549.
6. Skolyszewski J, Korzeniowski S, Reinfuss M. The reirradiation of recurrences of and neck cancer. Br J Radiol 1980;53:462-465.
7. Jeremic B, Djuric L, Mijatovic L. Incidence of radiation myelitis of the cervical spinal cord at doses of 5500 cGy or greater. Cancer 1991;68:2138-2141.
8. Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994;29:687-698.
9. Emami B, Marks JE. Retreatment of recurrent carcinoma of the head and neck by afterloading interstitial 192Ir implant. Laryngoscope 1983;93:1345-1347.
10. Yokes EE, Haraf DJ, Mick R, McEvilly JM, Weichselbaum RR. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994;12:2351-2359.
11. Coughlin CT, Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Semin Oncol 1989;16(4 Suppl 6):31-43.
12. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
13. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
14. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
15. Yokes EE, Moormeier JA, Ratain MJ, et al. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol 1992;29:178-184.
16. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
17. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-3497.
18. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995;22(3 Suppl 6):70-74.
19. Chang AY, Kim K, Click J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993;85388-85394.
20. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-263.
21. Klastersky J, Sculier JP, Bureau G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. J Clin Oncol 1989;7:1087-1092.
22. Klastersky J, Sculier JP, Ravez P, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986;4:1780-1786.
23. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251.
24. Forastiere AA. Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 1993;20 (4 Suppl 3):56-60.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
26. Ridge JA. Squamous cancer of the head and neck: surgical treatment of local and regional recurrence. Semin Oncol 1993;20:419-429.
27. Williams RG. Recurrent head and neck cancer: the results of treatment. Br J Surg 1974;61:691-697.
28. Wang CC. Re-irradiation of recurrent nasopharyngeal carcinoma-treatment techniques and results. Int J Radiat Oncol Biol Phys 1987;13:953-956.
29. Haraf DJ, Weichselbaum RR, Yokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol 1996;7:913-918.
30. Chmura SJ, Yokes EE, Garofalo M, et al. Long-term outcome of re-irradiation with concomitant chemotherapy for locally recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2003;57(2 Suppl): S409-S410.
31. Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001;51:1299-1304.
32. Spencer S, Wheeler R, Peters G, et al. Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck 2003;25:118-122.